KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Current Investments: 2018-2025

Historic Cash & Current Investments for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $287.6 million.

  • Castle Biosciences' Cash & Current Investments rose 2.78% to $287.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 10.76%. This contributed to the annual value of $293.1 million for FY2024, which is 20.58% up from last year.
  • Latest data reveals that Castle Biosciences reported Cash & Current Investments of $287.6 million as of Q3 2025, which was up 4.23% from $275.9 million recorded in Q2 2025.
  • Castle Biosciences' Cash & Current Investments' 5-year high stood at $407.0 million during Q1 2021, with a 5-year trough of $225.5 million in Q2 2023.
  • In the last 3 years, Castle Biosciences' Cash & Current Investments had a median value of $259.7 million in 2024 and averaged $258.3 million.
  • In the last 5 years, Castle Biosciences' Cash & Current Investments soared by 312.54% in 2021 and then decreased by 26.76% in 2022.
  • Quarterly analysis of 5 years shows Castle Biosciences' Cash & Current Investments stood at $329.6 million in 2021, then declined by 21.54% to $258.6 million in 2022, then declined by 6.00% to $243.1 million in 2023, then grew by 20.58% to $293.1 million in 2024, then grew by 2.78% to $287.6 million in 2025.
  • Its Cash & Current Investments stands at $287.6 million for Q3 2025, versus $275.9 million for Q2 2025 and $275.2 million for Q1 2025.